Vaderis Therapeutics secured an oversubscribed $152 million Series B to advance engasertib (VAD-044) in hereditary hemorrhagic telangiectasia. The financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX and included participation from multiple funds and existing investors. The company’s funding is aimed at pushing a Phase III-ready path in HHT, highlighting investor appetite for later-stage rare disease where clear clinical endpoints and high unmet need can compress time-to-value. For biotech financing watchers, the oversubscription signals that capital markets are still willing to underwrite late-stage risk—when the therapeutic area has both regulatory urgency and strong differentiated positioning.